JP2012524796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524796A5 JP2012524796A5 JP2012507354A JP2012507354A JP2012524796A5 JP 2012524796 A5 JP2012524796 A5 JP 2012524796A5 JP 2012507354 A JP2012507354 A JP 2012507354A JP 2012507354 A JP2012507354 A JP 2012507354A JP 2012524796 A5 JP2012524796 A5 JP 2012524796A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- following formula
- optionally substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- -1 cycloheteroalkyl Chemical group 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- 0 CC1(C)N=C(CC(C(*)Cc2c3cccc2)C3C#N)OC1 Chemical compound CC1(C)N=C(CC(C(*)Cc2c3cccc2)C3C#N)OC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17127309P | 2009-04-21 | 2009-04-21 | |
| US61/171,273 | 2009-04-21 | ||
| PCT/US2010/031916 WO2010124005A1 (en) | 2009-04-21 | 2010-04-21 | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524796A JP2012524796A (ja) | 2012-10-18 |
| JP2012524796A5 true JP2012524796A5 (enExample) | 2013-06-06 |
| JP5734957B2 JP5734957B2 (ja) | 2015-06-17 |
Family
ID=43011462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507354A Expired - Fee Related JP5734957B2 (ja) | 2009-04-21 | 2010-04-21 | ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9359303B2 (enExample) |
| EP (1) | EP2421862B1 (enExample) |
| JP (1) | JP5734957B2 (enExample) |
| WO (1) | WO2010124005A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011301B (zh) * | 2017-05-27 | 2019-06-28 | 山东省联合农药工业有限公司 | 一种2-（2-甲氧基苯基）-5-氧代四氢呋喃-3-羧酸的制备方法 |
| KR20220041847A (ko) | 2019-07-30 | 2022-04-01 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 섬유성 병리를 치료하기 위한 화합물 및 방법 |
| WO2022164996A1 (en) * | 2021-01-29 | 2022-08-04 | Mayo Foundation For Medical Education And Research | Methods of treating ocular fibrotic pathologies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3912740A (en) | 1974-02-28 | 1975-10-14 | Us Health | Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds |
| DK297275A (da) | 1974-08-07 | 1976-02-08 | Aspro Nicholas Ltd | Isoquinolinderivater |
| US3939165A (en) | 1974-11-14 | 1976-02-17 | Morton-Norwich Products, Inc. | 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride |
| US4346090A (en) | 1977-07-21 | 1982-08-24 | Ayerst, Mckenna & Harrison Ltd. | 13-Chloro-benzocycloheptapyridoisoquinolines and use as neuroleptics |
| NL8202467A (nl) | 1981-06-18 | 1983-01-17 | Univ Northeastern | Oraal-effectieve aporfineverbindingen. |
| US4678791A (en) * | 1985-05-07 | 1987-07-07 | Pennwalt Corporation | 6-phenyl-1,2-3,4,4a,5-6,10b-octahydrobenz(h)isoquinolines useful for treating depression |
| US4737503A (en) | 1986-10-08 | 1988-04-12 | Vipont Laboratories, Inc. | Method for inhibiting the release of histamine |
| US5047536A (en) | 1989-03-17 | 1991-09-10 | Purdue Research Foundation | Hexahydrobenzo(A)phenanthridine compounds |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) * | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| GB8917333D0 (en) | 1989-07-28 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5635506A (en) | 1990-06-26 | 1997-06-03 | Research Corporation Technologies, Inc. | 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents |
| IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
| US5266702A (en) | 1990-09-19 | 1993-11-30 | Council Of Scientific & Industrial Research | 1,3-oxazoline compounds useful as anionic initiators suitable for polymerization of vinyl polymers |
| US5216018A (en) | 1992-02-14 | 1993-06-01 | Du Pont Merck Pharmaceutical Company | Hydroisoindolines and hydroisoquinolines as psychotropic |
| ATE386724T1 (de) | 1992-05-26 | 2008-03-15 | Purdue Research Foundation | Substituierte hexahydrobenzo(a) phenanthridine |
| US5438131A (en) | 1992-09-16 | 1995-08-01 | Bergstrom; Donald E. | 3-nitropyrrole nucleoside |
| CN1046723C (zh) | 1993-04-06 | 1999-11-24 | 艾博特公司 | 四环化合物、含有它们的药物组合物及其用途 |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| WO1996038435A1 (en) * | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
| US5554621A (en) | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
| DK0845988T3 (da) | 1995-08-18 | 2002-04-02 | Purdue Research Foundation | Hidtil ukendte kondenserede isoquinoliner som dopaminreceptorligander |
| FR2764890B1 (fr) | 1997-06-24 | 1999-08-27 | Adir | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| AU4536599A (en) | 1999-06-21 | 2001-01-09 | Geochemistry Research Limited | Metal-rich silica products from geothermal and synthetic aqueous systems nen wie |
| US6733797B1 (en) | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
| BR0206402A (pt) | 2001-01-16 | 2006-01-17 | Purdue Research Foundation | Processo de tratamento de disfunção relacionada a dopamina por administração de um agonista de receptor de dopamina d1 inteiro e sem indução de tolerância |
| ATE406896T1 (de) | 2002-02-15 | 2008-09-15 | Darpharma Inc | Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten |
| AU2004308413A1 (en) | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
| WO2006012640A2 (en) | 2004-07-21 | 2006-02-02 | Darpharma, Inc. | Method of administration of dopamine receptor agonists |
| US7563805B2 (en) | 2005-05-19 | 2009-07-21 | Daiichi Pharmaceutical Co., Ltd. | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
| AR056695A1 (es) | 2005-10-17 | 2007-10-17 | Wyeth Corp | Tetrahidroquinolinas, su sintesis e intermediarios |
| EP2010541A2 (en) | 2006-02-21 | 2009-01-07 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
-
2010
- 2010-04-21 WO PCT/US2010/031916 patent/WO2010124005A1/en not_active Ceased
- 2010-04-21 US US13/265,454 patent/US9359303B2/en not_active Expired - Fee Related
- 2010-04-21 JP JP2012507354A patent/JP5734957B2/ja not_active Expired - Fee Related
- 2010-04-21 EP EP10767711.4A patent/EP2421862B1/en not_active Not-in-force